LAMTOR5 and breast carcinoma: HBXIP functions as an oncogenic transcriptional coactivator of various transcription factors (TFs), such as SP1, TF-IID, STAT3, CREB, and E2F1, in the promotion of breast cancer tumorigenesis and progression6–8.